Background: The aim of this study was to evaluate practicable predictors of 5-year disease-free survival (DFS) and impact of 5-fluorouracil (5-FU)-based adjuvant chemotherapy in stage IIa and IIb colon cancer. Materials and Methods: A total of 1474 patients with stage II colon cancer were enrolled in study. The independent predictors of 5-year DFS and the benefits of adjuvant chemotherapy were analyzed for patients with stage IIa (n = 771) and IIb (n = 703). Results: The incidences of pretreatment anemia, hypoalbuminemia, emergent surgery, and lymphovascular invasion (LVI) corresponded significantly to an advanced T-stage in patients with stage II colon cancer. Although the incidence of surgical morbidity was not different between stage IIa...
WOS: 000348335000005PubMed ID: 24852857Background. A high-risk group of patients with stage II colon...
PURPOSE: A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5...
Background: It is uncertain whether adjuvant chemotherapy (CMT) improves survival in patients with l...
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves su...
BACKGROUND AND PURPOSE: For patients with stage II colon cancer, the use of adjuvant chemotherapy re...
Summary: Background: There have been few previous studies regarding survival and predictive factors...
PURPOSE: We investigated the prognostic factors for recurrence in Korean patients with stage II colo...
Utility of adjuvant chemotherapy for stage II cancer remains a matter of debate. Clinical guidelines...
WOS: 000322750700010PubMed ID: 23818348Purpose: This study aimed at comparing the disease-free survi...
Purpose: Adjuvant chemotherapy is currently recommended for Stage IIIA colon cancers. This study aim...
Purpose: The goal of this analysis was to determine whether fluorouracil (FU) and folinic acid (leuc...
Background: Stratification of patients with stage III colon cancer into low (T1-3N1) and high (T4 an...
BackgroundA prospective, pooled analysis of six randomised phase 3 trials was done to investigate di...
Background: The traditional endpoint for colon adjuvant clinical trials (CT) is OS, with 5 years (yr...
Background: Adjuvant chemotherapy (AC) in Stage II Colon Cancer (CC) is still under debate. Choice s...
WOS: 000348335000005PubMed ID: 24852857Background. A high-risk group of patients with stage II colon...
PURPOSE: A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5...
Background: It is uncertain whether adjuvant chemotherapy (CMT) improves survival in patients with l...
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves su...
BACKGROUND AND PURPOSE: For patients with stage II colon cancer, the use of adjuvant chemotherapy re...
Summary: Background: There have been few previous studies regarding survival and predictive factors...
PURPOSE: We investigated the prognostic factors for recurrence in Korean patients with stage II colo...
Utility of adjuvant chemotherapy for stage II cancer remains a matter of debate. Clinical guidelines...
WOS: 000322750700010PubMed ID: 23818348Purpose: This study aimed at comparing the disease-free survi...
Purpose: Adjuvant chemotherapy is currently recommended for Stage IIIA colon cancers. This study aim...
Purpose: The goal of this analysis was to determine whether fluorouracil (FU) and folinic acid (leuc...
Background: Stratification of patients with stage III colon cancer into low (T1-3N1) and high (T4 an...
BackgroundA prospective, pooled analysis of six randomised phase 3 trials was done to investigate di...
Background: The traditional endpoint for colon adjuvant clinical trials (CT) is OS, with 5 years (yr...
Background: Adjuvant chemotherapy (AC) in Stage II Colon Cancer (CC) is still under debate. Choice s...
WOS: 000348335000005PubMed ID: 24852857Background. A high-risk group of patients with stage II colon...
PURPOSE: A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5...
Background: It is uncertain whether adjuvant chemotherapy (CMT) improves survival in patients with l...